Basf as

Pronova Biopharma Norge as

Other

Tore Skjæret

David Alan Fraser

Hilde Steineger

Ragnar Hovland

Anne Kristin Holmeide

Morten Brændvang

David A Fraser

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R, Rand X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Substituted fatty acids for treating non-alcoholic steatohepatitis

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R, R, R, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Fatty acid derivatives for treating non-alcoholic steatohepatitis

The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein RI, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R, R2, R3, X and Y are as defined in the specification;or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R, and X, are as defined in the specification;or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R, Rand X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.

Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I):  or a pharmaceutically acceptable salt, or ester thereof, wherein Rand Rare independently chosen from a hydrogen atom or linear, branched, and/or cyclic C-Calkyl groups, with the proviso that Rand Rare not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

Methods of treatment using lipid compounds

Methods for the efficient synthesis of fatty acid derivatives and their intermediates are provided.

Methods of preparing fatty acid derivatives

The present disclosure relates to lipid compounds of the general formula (I):R1-O&#x2014;C(R2)(R3)-X&#x2003;&#x2003;(I)wherein Ris a C-Calkyl group, a C-Calkenyl group having 1-6 double bonds, or a C-Calkynyl group having 1-6 triple bonds; Rand Rare the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

Growing community of inventors

Oslo, Norway

Tore Skjæret